Avicidin yttrium-90 beta-emitting radionuclide administered after a murine antibody complex specific to tumors data

NERX presented interim results of a Phase I/II trial at the Antibody-Based Therapeutics Conference in Boston. At 100 mCi/m

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE